97 results
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
taxable disposition, which gain may be offset by certain U.S.-source capital losses of the Non-U.S. Holder (even though the Non-U.S. Holder
424B5
RVNC
Revance Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
6:39am
be specified by an applicable income tax treaty, on gain realized upon the sale or other taxable disposition, which gain may be offset by certain U.S
8-K
EX-99.1
cp0chas1
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-10.1
3emwb62z5o5xirhff
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
8-K
EX-99.1
f553j
8 Jan 24
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
8:01am
8-K
EX-99.1
3kry9fb2pmaks
8 Nov 23
Provides Corporate Update
4:09pm
424B5
9hok l2sg8r8ggh
13 Sep 22
Prospectus supplement for primary offering
9:13pm
424B5
3xxwoov3 ex41lnay
12 Sep 22
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
7vg5hljrk6l4szbb
10 May 22
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
4:13pm